IDIR® TEST: A WORLD-FIRST FOR NON-COMMUNICABLE DISEASE PREVENTION

The IDIR® urine test *(Identification of Insulin Resistance)* : Innovative Screening for Cardiometabolic Disease Development Risk

1. INNOV BIOTECH: COMMITED TO NON-COMMUNICABLE DISEASE PREVENTION

Innov Biotech deploys innovative and accessible biotechnology solutions for the benefit of populations. It produces and distributes the first screening test for insulin resistance, the IDIR® urine test.

2. IDIR®, THE KEY TO DETECTING AND QUANTIFYING INSULIN RESISTANCE

The IDIR® test enables the detection and quantification of insulin resistance, a common risk factor for cardiometabolic diseases present up to a decade before symptoms appear. Insulin resistance is reversible through non-drug, educational and medical therapies, making it possible to delay or even prevent type 2 diabetes, cardiovascular diseases and other cardiometabolic conditions.

Insulin resistance currently affects between 15.5% and 46.5% of the global population. By reliably, rapidly, and non-invasively detecting insulin resistance, the IDIR® test addresses an unmet need: assessing the metabolic health status of populations well in advance of the onset of diseases.

3. A PATENTED AND CERTIFIED INNOVATION

Developed by the Sys2Diag Joint Research Unit *(CNRS-ALCEN)*, the IDIR® test employs patented technology based on the enzymatic quantification of branched-chain amino acids (BCAAs). The IDIR® test is specifically designed to measure abnormal levels of BCAAs in urine, which are correlated with insulin resistance. Numerous scientific studies have identified BCAAs as the most early metabolic biomarkers of insulin resistance.

The IDIR® test has undergone clinical validation in France, with prepublication in The Lancet, as well as in Senegal. It holds CE marking and is registered with the ANSM (French National Agency for the Safety of Medicines and Health Products).

The IDIR® test has been developed by Sys2Diag (CNRS-ALCEN)

4. A WORLD-FIRST IN TERMS OF RELIABILITY, SIMPLICITY AND LOW COST

The IDIR® test is pioneering in the realm of insulin resistance screening, notable for its:

Non-invasive: Conducted with urine samples, the test ensures a straightforward and comfortable experience for the patient.

Precise quantification: IDIR® being quantitative in nature, allows for tracking the progression of insulin resistance and real-time assessment of the impact of changes.

Swiftness: Up to 45 urine samples can be analysed simultaneously, delivering results within just 60 minutes, combining efficiency and speed.

Easy-to-Use: The IDIR® test requires minimal technical equipment and can be implemented in any clinical laboratory or point-of-care setting.

Cost-Effective: IDIR® offers an economically attractive solution when compared to existing blood tests.

The IDIR® urine test revolutionizes the approach to insulin resistance screening and the prevention of cardiometabolic diseases, providing a precise, fast, and cost-effective solution suitable for both individual use and large-scale screening campaigns.

5. LOCAL PRODUCTION: A STEP TOWARDS PHARMACEUTICAL SOVEREIGNTY

One of the major advantages of the IDIR® test is its ability to be produced locally. Its design facilitates a seamless technology transfer, paving the way for the establishment of a domestic production unit. This production autonomy not only enhances pharmaceutical sovereignty for countries but also provides an economically advantageous solution.

6. A MAJOR INNOVATION TO PREVENT CARDIOMETABOLIC DISEASES WORLDWIDE

The IDIR® test developed by Sys2Diag and distributed by Innov Biotech is much more than a simple screening tool. It symbolises a proactive approach to the growing epidemic of cardiometabolic diseases. With its ease of use, certified reliability, low economic cost and the potential for local production, the IDIR® test represents a major advancement in the prevention of cardiometabolic diseases worldwide.

By enabling large-scale global screening for insulin resistance, IDIR® serves as an innovative and tangible tool in the prevention of cardiometabolic diseases.

IDIR® : DETECT THE INVISIBLE TO ANTICIPATE CARDIOMETABOLIC DISEASES.

INNOV BIOTECH